Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study

Les cellules souches en ingénierie des tissus ostéoarticulaires et vasculaires

“…Un des objectifs majeurs de ces constructions hybrides est en effet de présenter, à terme, au contact du sang, une surface cellulaire non thrombogène [51]. En ingénierie vasculaire, des résultats cliniques probants sont rapportés avec des biomatériaux (dégradables ou non) associés -préa-lablement à leur implantation -à des cellules autologues dans la réalisation de pontages [34], de constructions vasculaires totalement autologues [35], ou dans la chirurgie des cardiopathies congénitales [36]. Selon les cas, les cellules ensemencées sont soit matures soit immatures et, dans ce cas, elles se différencieront in situ .…”

Spatial patterning of endothelial cells and vascular network formation using ultrasound standing wave fields

“…The first commercially available tissues included skin substitutes and cartilage replacements (Chung and Burdick, 2008;Priya et al, 2008;Jaklenec et al, 2012). More recently, bladder analogs (Atala et al, 2006) and urethral segments (Atala et al, 1999;El-Kassaby et al, 2003;Raya-Rivera et al, 2011) have been successfully implanted into patients, and artificial blood vessels (Shin'oka et al, 2001;L'Heureux et al, 2007;McAllister et al, 2009;Olausson et al, 2012), trachea (Macchiarini et al, 2008;Baiguera et al, 2010), and corneal tissue (Griffith et al, 2009) have reached clinical trials. In contrast, attempts to fabricate larger functional organs that have more complex cellular organization, such as liver, heart, and kidney, have been unsuccessful (Badylak et al, 2012).…”

Regenerative medicine, tissue engineering and vascular surgery: twenty first century clinical challenges

“…Grafts with an average length of 23.2 cm (range 14-30 cm) were implanted into nine patients (one patient was excluded prior to implantation because of gastrointestinal haemorrhage) and were assessed for both mechanical stability and effectiveness during the safety phase (0-3 months) and after haemodialysis was started. While the patency rates were good, it was possible to use the implanted graft for haemodialysis for longer than 12 months in only three patients [9].…”

“…McAllister and colleagues [9] have recently reported the successful implantation of a completely biologic tissueengineered graft for vascular access in ten patients with end stage renal disease receiving haemodialysis. Patency rates at 1 and 6 months were 78 and 60%, respectively.…”